A Phase I/II Clinical Trial of pNGVL4a-Sig/E7 (Detox)/HSP70 [human papillomavirus 16 E7 HSP70] for the Treatment of Patients With HPV 16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Human papillomavirus 16 E7 HSP70 vaccine (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- 20 Jul 2018 Biomarkers information updated
- 20 May 2009 Lead trial investigator (Trimble CL) added as reported by ClinicalTrials.gov.
- 22 Jan 2008 Status changed from recruiting to in progress.